Lycia Therapeutics is headquartered at 400 East Jamie Court, Suite 200, South San Francisco, California 94080.
Lycia is incorporated in Delaware.
Lycia commenced operations in 2019.
Lycia’s initial public offering (IPO) occurred on October 23, 2026.
Lycia's fiscal year ends on December 31.
Lycia's common stock trades on the Nasdaq Global Select Market under the ticker symbol "LYCA".
55081P 100
Lycia shares can be bought through a broker of your choice. Lycia does not offer a direct stock purchase plan.
Lycia has never declared or paid any cash dividends on its common stock and does not anticipate paying any cash dividends on its common stock in the foreseeable future.
No.
Computershare Trust Company, N.A.
150 Royall Street
Canton, MA 02021
Phone: 1 (800) 736-3001 (Toll Free Number)
Shareholder online inquiries can be submitted through: www-us.computershare.com/investor/Contact
If you hold shares directly in your own name, please contact our transfer agent, Computershare, using the details above or at: www-us.computershare.com/investor/Contact. If you hold shares through a bank or brokerage account, please contact your broker.
KPMG LLP
Fenwick & West LLP
Lycia's filings with the Securities and Exchange Commission (SEC) are available in the Investors section of this website. All filings can also be viewed on the SEC's website at www.sec.gov.
Lycia's news releases are available in the News section of this website. You can also sign up to receive news releases and SEC filing notices by email.
Please email IR@lyciatx.com.
Please email media@lyciatx.com.